{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:06:02Z","timestamp":1785308762756,"version":"3.55.0"},"reference-count":20,"publisher":"Baskent University","issue":"Supp 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.mesot2025.o42","type":"journal-issue","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:28:34Z","timestamp":1785234514000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Hart A, Singh D, Brown SJ, Wang JH, Kasiske BL. Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review. Clin Transplant. 2021;35(7):e14320. doi:10.1111\/ctr.14320","DOI":"10.1111\/ctr.14320"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13(1):182-192. doi:10.2215\/CJN.00700117","DOI":"10.2215\/CJN.00700117"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379(12):1150-1160. doi:10.1056\/NEJMra1802677","DOI":"10.1056\/NEJMra1802677"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Lefaucheur C, Louis K, Morris AB, et al; STAR 2022 Working Group. Clinical recommendations for posttransplant assessment of anti-HLA (human leukocyte antigen) donor-specific antibodies: a sensitization in transplantation: assessment of risk consensus document. Am J Transplant. 2023;23(1):115-132. doi:10.1016\/j.ajt.2022.11.013","DOI":"10.1016\/j.ajt.2022.11.013"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Sellar\u00e9s J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-399. doi:10.1111\/j.1600-6143.2011.03840.x","DOI":"10.1111\/j.1600-6143.2011.03840.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Fichtner A, Gauch\u00e9 L, S\u00fcsal C, et al; CERTAIN study group. Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients: a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN). Pediatr Nephrol. 2025;40(2):491-503. doi:10.1007\/s00467-024-06487-2","DOI":"10.1007\/s00467-024-06487-2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Engen RM, Park GE, Schumacher CS, et al. Donor-specific antibody surveillance and graft outcomes in pediatric kidney transplant recipients. Transplantation. 2018;102(12):2072-2079. doi:10.1097\/TP.0000000000002310","DOI":"10.1097\/TP.0000000000002310"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2012;12(12):3355-3362. doi:10.1111\/j.1600-6143.2012.04251.x","DOI":"10.1111\/j.1600-6143.2012.04251.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Charnaya O, Tuchman S, Moudgil A. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort. Pediatr Transplant. 2018;22(2). doi:10.1111\/petr.13108","DOI":"10.1111\/petr.13108"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Strommen AM, Moss MC, Goebel J, Bock M. Donor-specific antibodies in a pediatric kidney transplant population: prevalence and association with antiproliferative drug dosing. Pediatr Transplant. 2019;23(6):e13511. doi:10.1111\/petr.13511","DOI":"10.1111\/petr.13511"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Schwartz GJ, Mu\u00f1oz A, Schneider et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637. doi:10.1681\/ASN.2008030287","DOI":"10.1681\/ASN.2008030287"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Schwartz GJ, Schneider MF, Maier PS, et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82(4):445-453. doi:10.1038\/ki.2012.169","DOI":"10.1038\/ki.2012.169"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Tambur AR, Campbell P, Claas FH, et al. Sensitization in transplantation: assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant. 2018;18(7):1604-1614. doi:10.1111\/ajt.14752","DOI":"10.1111\/ajt.14752"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Cioni M, Nocera A, Innocente A, et al. De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients. J Immunol Res. 2017;2017(1):1747030. doi:10.1155\/2017\/1747030","DOI":"10.1155\/2017\/1747030"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Miettinen J, Per\u00e4saari J, Lauronen J, et al. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol. 2012;27(6):1011-1019. doi:10.1007\/s00467-012-2101-4","DOI":"10.1007\/s00467-012-2101-4"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Gulleroglu K, Baskin E, Bayrakci US, et al. Antibody-mediated rejection and treatment in pediatric patients: one center's experience. Exp Clin Transplant. 2013;11(5):404-407. doi:10.6002\/ect.2012.0242.","DOI":"10.6002\/ect.2012.0242"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Steggerda JA, Kim IK, Haas M, et al. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies. Pediatr Transplant. 2017;21(8):e13079. doi:10.1111\/petr.13079","DOI":"10.1111\/petr.13079"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157-1167. doi:10.1111\/j.1600-6143.2012.04013.x","DOI":"10.1111\/j.1600-6143.2012.04013.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Tait BD, S\u00fcsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19-47. doi:10.1097\/TP.0b013e31827a19cc","DOI":"10.1097\/TP.0b013e31827a19cc"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Hafeez MS, Awais SB, Razvi M, et al. HLA mismatch is important for 20-year graft survival in kidney transplant patients. Transpl Immunol. 2023;80:101861. doi:10.1016\/j.trim.2023.101861","DOI":"10.1016\/j.trim.2023.101861"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:38:34Z","timestamp":1785307114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2026\/24\/6\/2\/110\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"Supp 2","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2025.o42","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}